@article{b573ebd8fe1f42eb88e4938030f8919c,
title = "Commentary: Current Status of Gene Therapy for Spinal Muscular Atrophy",
keywords = "AAV9, AVXS-101, Survival Motor Neuron (SMN), Zolgensma, gene therapy, onasemnogene abeparvovec, spinal muscular atrophy (SMA)",
author = "Wilfried Rossoll and Singh, {Ravindra N.}",
note = "Funding Information: The first incarnation of the Welleye was developed by all three authors as part of a wellbeing policy document for the United Arab Emirates' National Program for Happiness and Wellbeing. The authors would like to express their sincere gratitude to the team who were involved in the policy document, in particular Mohamed Abdullah and Tarek Abu Fakhr. During further development, KL was supported by Marie Sk{\l}odowska-Curie Individual Fellowship from the European Commission (Project name: Mind The Gap; Project number: 845342) and LK was supported by the National Institute for Health Research (NIHR) Applied Research Centre (ARC) West Midlands, grant number NIHR200165. The University of Birmingham supported the open access publication of the work. ",
year = "2022",
month = may,
day = "17",
doi = "10.3389/fncel.2022.916065",
language = "English (US)",
volume = "16",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",
}